Top Health Tech Companies in Dublin (80)
InterSystems builds the software that makes complex systems work—reliably, securely, and at scale. For more than 45 years, we’ve been the information engine behind some of the world’s most mission-critical applications in healthcare, government, and business. Our data management, integration, and analytics technologies help organizations connect disparate systems, turn data into insight, and deliver better outcomes. From enabling interoperable healthcare and...
InterSystems's Top Stability & Growth Strengths
Resilient & Sustainable Growth: Growth is described as measured and predictable, with signals such as modest headcount expansion, sustained operating scale, and continued momentum rather than volatility.
Innovation-Driven Growth: Recent major releases across IRIS/IRIS for Health/Health Connect and new AI-focused offerings indicate ongoing R&D velocity that broadens capabilities and use cases.
Strong Market Position & Advantage: Repeated industry accolades for Shared Care Records/HIE and regional acute EHRs in 2026 point to durable competitive standing in core healthcare markets.
Optum, part of the UnitedHealth Group family of businesses, is a global organization that delivers care, aided by technology to help millions of people live healthier lives. The work you do with our team will directly improve health outcomes by connecting people with the care, pharmacy benefits, data and resources they need to feel their best. Here, you will find...
.jpg)
Optum's Top Stability & Growth Strengths
Strong Revenue Growth: Consolidated revenues increased from $253 billion in 2024 to $270.6 billion in 2025, with quarterly gains such as Q4 2025 up 8% year over year. Growth was led primarily by Optum Rx and supported by steady contributions from Optum Insight.
Market Expansion: Expansion through acquisitions such as Holston Medical Group (August 2025) and Alegeus (July 2026), alongside earlier combinations like Change Healthcare and Atrius Health, broadened capabilities across care, pharmacy, and payments. These moves extend Optum’s platform into adjacent services and operating domains.
Diversified Revenue Streams: A multi-segment model—Rx, Insight, and Health—helps sustain aggregate growth even as individual lines vary, with pharmacy and technology businesses offsetting care-delivery softness. Parent-company commentary continuing to frame Optum as a growth engine and raising 2026 guidance underscores the benefit of this portfolio effect.
Centene provides healthcare solutions to individuals across the United States with more than 23 million members nationwide.
Centene Corporation's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue is rising with multiple quarters of year-over-year increases, a higher 2025 premium and service revenue outlook, and record trailing-twelve-month totals.
Strong Market Position & Advantage: The company is the largest Medicaid managed care organization and the leading ACA Marketplace carrier, with nationwide operations and sustained industry recognition.
Market Expansion: Membership is growing in the ACA Marketplace and Medicare prescription drug plans, alongside ongoing footprint expansion and key state Medicaid contract wins.
At EMA Aesthetics we believe that life is an art and everything we do embraces that art. Our approach is avant-garde designed to challenge the status quo. We focus on combination therapy that enhances aesthetic procedures. Results over sentiment. At EMA Aesthetics we regard customers as our partners. Working together, we provide best-in-class aesthetic solutions that yield beautiful returns and...
X-Bolt brings simplicity and efficiency to trauma surgery, whilst improving quality of life for patients
The Wellola team believes only the sickest of the sick should be hospitalised and that the future of healthcare is preventative, community-based and supported by digital tools. Wellola prides itself in being highly user-focused, reliable, robust and easy-to-use. Our team have unique, in-depth sector know-how, our pricing model is extremely cost effective and our business model is scalable for national...
Webdoctor.ie is Ireland’s award-winning online GP service. As featured in Deloitte’s Fast 50 Technology Awards, Webdoctor.ie is an Irish-owned health technology platform founded and led by healthcare professionals. With 40+ Irish Medical Council registered doctors on its team, Webdoctor.ie can be accessed from anywhere in Ireland with an internet connection on a phone, tablet or computer via the website or...
Every day, millions of patients, caregivers and providers around the world rely on Baxter’s leading portfolio of diagnostic, critical care, nutrition, kidney care, hospital and surgical products and solutions. For 90 years, we’ve been making an impact at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, therapies and...
Baxter International Inc.'s Top Stability & Growth Strengths
Strong Market Position & Advantage: Baxter is a leader in U.S. IV solutions and a top contender in connected-care hospital beds and surgical hemostats, underscoring durable share in core hospital categories. This positioning supports resilience despite category- and region-specific competition.
Product Line Growth: Ongoing updates to infusion technologies and continued launches in injectables and advanced surgery indicate a healthy product refresh cadence. FDA clearances and connected-care enhancements help sustain installed-base momentum.
Future-Ready Strategy: Portfolio reshaping (Kidney Care divestiture) and new leadership focused on execution and continuous improvement signal a sharpened hospital-centric strategy. Deleveraging and supply-chain initiatives aim to improve stability and long-term growth capacity.
Abi Global Health delivers telemedicine solutions in 37 countries across 6 continents. Our unique artificial intelligence and machine learning technology enables our network of over 1,000 healthcare professionals to provide quick answers to users in 24 languages across a choice of interfaces
Swiftqueue Enterprise Scheduling is like Air Traffic Control for Healthcare Appointments and Referrals. Our Patient First solutions deliver co-ordinated healthcare appointments and referral management in Ireland, UK & USA. We have helped our customer's significantly reduce the cost of clinic administration and deliver a demonstrable ROI. Our rapid deployment templates and integration APIs can deliver results for our customers in...
We are a biotech longevity company on a mission to confront aging and age-related diseases. We’re building a coalition of the best scientists, physicians and investors to develop therapies and products that will help people experience better health for longer in their lives. We are organized to drive scientific innovation with speed and agility to market
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of...
Bristol Myers Squibb's Top Stability & Growth Strengths
Strong Market Position & Advantage: Feedback suggests BMS holds a top‑tier global position with anchor franchises like Eliquis and Opdivo and a broad oncology footprint including cell therapies, reinforcing sustained competitive advantage.
Product Line Growth: Feedback suggests the company’s “growth portfolio” of newer medicines is expanding strongly, with assets such as Reblozyl, Breyanzi, Camzyos, Opdualag and Cobenfy helping to offset legacy declines.
Future-Ready Strategy: Feedback suggests recent acquisitions and collaborations (Karuna/Cobenfy, RayzeBio, Mirati, BioNTech) broaden modalities and late‑decade growth drivers, positioning the company to sustain leadership beyond current headwinds.
WhatClinic.com helps patients find, compare and book the right clinic for the treatment they need. With over 16 million annual users, and over 120,000 clinics listed, WhatClinic.com is the patient's first choice for clear and transparent information about clinics within the elective, self-pay healthcare sector. We provide detailed listings for doctors, dentists, beauty and cosmetic surgery, physiotherapy, fertility, holistic clinics...
LGC is a leading, global life science tools company, providing mission-critical components and solutions into high-growth application areas across the human healthcare and applied market segments. Its high quality product portfolio is comprised of mission-critical tools for genomic analysis and for quality assurance applications, which are typically embedded and recurring within our customers’ products and workflows and are valued for...
LGC's Top Stability & Growth Strengths
Strong Market Position & Advantage: Holding the UK’s National Measurement Laboratory designation and Government Chemist role, plus leading positions in reference materials, proficiency testing, and agrigenomics/genotyping, reinforces defensible niche leadership. Acquisitions and widespread adoption of technologies like KASP genotyping underscore recognized authority in core segments.
Strong Revenue Growth: Reported revenue increased year over year in FY25, reversing the prior year’s dip. Adjusted EBITDA also rose, indicating improved top-line momentum alongside better operating results.
Future-Ready Strategy: Large-scale site expansions (Toronto, Guildford, Berlin) and integration of recent acquisitions point to capacity build-out and a scale-focused operating model. A new CEO, business-unit consolidation, and an Innovation Hub signal intent to sustain growth through portfolio development and execution.
Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With 50 years in business, operations in more than 35 countries and approximately 44,000 employees globally, Cardinal Health is essential to care. We are navigating the complexities of healthcare and providing scaled...
Cardinal Health's Top Stability & Growth Strengths
Strong Revenue Growth: Broad-based segment momentum is evident, with Pharmaceutical & Specialty Solutions and the “Other” businesses posting strong year-over-year revenue increases alongside profit expansion. Growth is further supported by increased specialty-pharmaceutical volumes and added distribution capacity for complex therapies.
Profitability: Segment profit and operating earnings are rising faster than revenue in recent periods, indicating improved earnings conversion. Management’s repeated increases to non-GAAP EPS guidance reinforce the view that profitability is strengthening.
Diversified Revenue Streams: Adjacency businesses (at-Home Solutions, Nuclear & Precision Health, OptiFreight) are growing quickly and contributing meaningfully to profit growth. Portfolio expansion through acquisitions is broadening the earnings base beyond core drug distribution.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for...
Becton Dickinson's Top Stability & Growth Strengths
Strong Market Position & Advantage: The company is repeatedly described as a leader across core categories like syringes, prefillable drug-delivery systems, blood collection, and infusion therapy, supported by broad global reach and large installed bases. This entrenched position aids customer stickiness and supports durable demand.
Resilient & Sustainable Growth: A substantial portion of revenue comes from everyday consumables and recurring platforms, which provides steadier sales through cycles. Consistent year-over-year revenue increases and diversified end-market exposure underpin an enduring growth profile.
Future-Ready Strategy: Management is reshaping the portfolio into a pure-play MedTech company and investing in manufacturing capacity and innovation to sharpen focus on higher-value growth areas. Guidance reaffirmations and targeted segment investments indicate disciplined execution toward long-term expansion.
ArisGlobal is transforming the way today’s most successful life sciences companies develop breakthroughs and bring new products to market. Our end-to-end drug development technology platform, LifeSphere®, integrates our proprietary cognitive computing engine to automate all core functions of the drug development lifecycle. Designed with deep expertise and a long-term perspective that spans more than 30 years, LifeSphere® boosts efficiency, ensures...
.png)
Spectrum.Life is a mental health and wellbeing innovator on a mission to change and protect as many lives as possible; delivering digital solutions for Corporate, Insurance and University Sectors. Spectrum.Life supports 2.5m users across 2,500 clients across Ireland & the UK. Our solutions are clinically backed and ensure that there is something for everyone- for wherever they are on the...
For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation, and as a future-focused organization, we’re continuing to drive forward with endurance in our steadfast pursuit to achieve the best outcomes for our patients in a rapidly changing world. We have been preparing for this period of value creation by investing in data, digital and...
Takeda's Top Stability & Growth Strengths
Strong Market Position & Advantage: Takeda is consistently placed among the global top 15–20 by revenue and is a clear category leader in GI/IBD, plasma-derived therapies, and dengue vaccines with broad international authorizations and WHO support. Subcutaneous ENTYVIO and new oncology approvals like FRUZAQLA broaden real‑world use and extend reach.
Profitability: Reported FY2025 operating profit rose 19.3% year over year and EPS nearly doubled despite a slight revenue decline, supported by lower amortization and restructuring expense. Core profitability remained broadly stable as Growth & Launch Products expanded their share.
Future-Ready Strategy: Management is investing through FY2026 to convert a late‑stage pipeline (e.g., oveporexton, rusfertide, zasocitinib) into multiple launches, with Growth & Launch Products prioritized as near‑term engines. A multi‑year transformation and efficiency program targeting significant savings by FY2028 is intended to fund launches and strengthen competitiveness.
